netFormulary
 Report : Medicines with links to NICE 08/03/2021 08:45:31

[Back]

Report looks at the links table and pulls back all the items in the formulary where there is a link with 'nice.org' in the URL

You can sort this table Medicines Link Name or Link URL by clicking on the title

Selecting the Medicine name will take you to the entry in the formulary, Selecting the Link name will follow the link

 
Medicines/Item Section Status Link Name / Link URL
Abatacept 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Abatacept 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Abatacept 10.01.03 Formulary NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
Abatacept 10.01.03 Formulary NICE TA568 Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal)
Abemaciclib 08.03.04.01 Formulary NICE TA579 Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
Abemaciclib 08.03.04.01 Formulary NICE TA563 Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Abiraterone 08.03.04.02 Non Formulary NICE TA387:Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Abiraterone 08.03.04.02 Non Formulary NICE TA259: Abiraterone for castration resistant prostate cancer
Adalimumab 13.05.03.02 Formulary NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa
Adalimumab 13.05.03.02 Formulary NICE TA146: Adalimumab for the treatment of adults with psoriasis
Adalimumab 10.01.03 Formulary NICE TA199: Psoriatic arthritis
Adalimumab 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Adalimumab 10.01.03 Formulary NICE TA455 : Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young peopl
Adalimumab 10.01.03 Formulary NICE TA460 : Adalimumab and dexamethasone for treating non-infectious uveitis
Adalimumab 10.01.03 Formulary NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor
Adalimumab 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Adalimumab 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Adalimumab 01.05.03 Formulary NICE TA187: Crohn’s disease - infliximab and adalimumab
Adalimumab 01.05.03 Formulary NICE TA460 : Adalimumab and dexamethasone for treating non-infectious uveitis
Adalimumab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Adefovir Dipivoxil 05.03.03.01 Restricted Use NICE TA96: Hep B - adefovir dipivoxil and pegylated interferon alpha-2a
Adefovir Dipivoxil 05.03.03.01 Restricted Use NICE CG165: Hepatitis B (chronic) - incorporates TA96
Adrenaline / Epinephrine 03.04.03 Formulary NICE CG134: Anaphylaxis: Assessment and referral after emergency treatment
Afatinib 08.01.05 Formulary NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
Aflibercept 08.01.05 Non Formulary NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Aflibercept 40mg/ml 11.99.99.99 Formulary NICE TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
Aflibercept 40mg/ml 11.99.99.99 Formulary NICE TA486: Aflibercept for treating choroidal neovascularisation
Aflibercept 40mg/ml 11.99.99.99 Formulary NICE TA346:Aflibercept for treating diabetic macular oedema
Aflibercept 40mg/ml 11.99.99.99 Formulary NICE TA294: Aflibercept solution for injection for treating wet age‑related macular degeneration
Aflibercept 40mg/ml 11.99.99.99 Formulary NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
Alemtuzumab 08.02.03 Formulary NICE TA312: Alemtuzumab for relapsing‑remitting multiple sclerosis
Alirocumab 02.12 Formulary NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Alteplase 02.10.02 Formulary NICE TA264: Ischaemic stroke (acute) - alteplase
Anti-D (Rh0) Immunoglobulin 14.05.03 Formulary NICE TA156: Anti-D in pregnant women
Apixaban 02.08.02 Formulary NICE TA275: Apixaban for AF
Apremilast 13.05.03 Formulary NICE TA372: Apremilast for psoriatic arthritis
Apremilast 13.05.03 Formulary NICE TA419: Apremilast for treating moderate to severe plaque psoriasis
Apremilast 13.05.03 Formulary NICE TA433 : Apremilast for treating active psoriatic arthritis
Aripiprazole 04.02.01 Formulary NICE TA292: Bipolar disorder (children) - aripiprazole
Aripiprazole 04.02.01 Formulary NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years
Arsenic Trioxide 08.01.05 Formulary NICE TA526 Arsenic trioxide for treating acute promyelocytic leukaemia
Atezolizumab 08.02.04 Formulary TA492 Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Atezolizumab 08.02.04 Formulary NICE TA492 Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Atezolizumab 08.02.04 Formulary NICE TA525 Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Atezolizumab 08.02.04 Formulary NICE TA 520 Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
Atezolizumab 08.02.04 Formulary NICE TA 639 Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer
Atezolizumab 08.02.04 Formulary NICE TA638 Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer
Atezolizumab 08.02.04 Formulary NICE TA618 Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal)
Atezolizumab 08.02.04 Formulary NICE TA584 Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
Avelumab 08.01.05 Formulary NICE TA645 Avelumab with axitinib for untreated advanced renal cell carcinoma
Axitinib 08.01.05 Formulary NICE TA333: Axitinib for advanced renal cell carcinoma
Azacitidine 08.01.03 Formulary NICE TA399: Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts
Azacitidine 08.01.03 Formulary NICE TA218: azacitidine for myelodysplastic syndromes
Baricitinib 10.01.03 Formulary NICE TA466 : Baricitinib for moderate to severe rheumatoid arthritis
Basiliximab 08.02.02 Non Formulary NICE TA85: Immunosuppressives in renal transplant (Adults)
Basiliximab 08.02.02 Non Formulary NICE TA99: Immunosuppressives in renal transplant (Children)
Belimumab 10.01 Formulary NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus
Bendamustine 08.01.01 Formulary NICE TA216: Bendamustine for CLL
Benralizumab 03.04.02 Formulary NICE TA 565 Benralizumab for treating severe eosinophilic asthma
Bevacizumab 08.01.05 Formulary Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal)
Bevacizumab 08.01.05 Formulary NICE TA214: Breast Cancer with taxane
Bevacizumab 08.01.05 Formulary NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab
Bevacizumab 08.01.05 Formulary NICE TA263: Breast cancer with capecitabine
Bisphosphonates 09.05.01.02 Non Formulary NICE TA464 : Bisphosphonates for treating osteoporos
Bivalirudin 02.08.01 Non Formulary NICE TA230 : Bivalirudin for the treatment of STEMI, 2011
Blinatumomab 08.02 Formulary NICE TA450 : Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
Blinatumomab 08.02 Formulary NICE TA589 Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity
Boceprevir 05.03.03.02 Formulary NICE TA253: hepatitis
Bortezomib 08.01.05 Formulary NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
Bortezomib 08.01.05 Formulary NICE TA129: Multiple myeloma - bortezomib
Bortezomib 08.01.05 Formulary NICE TA228: 1st line treatment of multiple myeloma
Bortezomib 08.01.05 Formulary NICE TA311: Bortezomib for induction therapy in multiple myeloma
Bortezomib 08.01.05 Formulary NICE TA 602 Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)
Bortezomib 08.01.05 Formulary NICE TA603 Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal)
Bosutinib 08.01.05 Formulary NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
Botulinum Toxin Type A 04.09.03 Formulary NICE TA605 Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea
Brentuximab vedotin 08.01.05 Formulary NICE TA524 Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Brentuximab vedotin 08.01.05 Formulary NICE TA577 Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
Brentuximab vedotin 08.01.05 Formulary NICE TA564 Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal)
Brentuximab vedotin 08.01.05 Formulary NICE TA446 : Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Brentuximab vedotin 08.01.05 Formulary TA641 Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma
Brigatinib 08.01.05 Formulary NICE TA571 Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
Brodalumab 13.05.03.02 Formulary NICE TA511 Brodalumab for treating moderate to severe plaque psoriasis
Cabazitaxel 08.01.05 Formulary NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
Cabozantinib 08.01.05 Formulary NICE TA463 : Cabozantinib for previously treated advanced renal cell carcinoma
Cabozantinib 08.01.05 Formulary NICE TA582 Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal)
Cabozantinib 08.01.05 Formulary NICE TA516 Cabozantinib for treating medullary thyroid cancer
Cabozantinib 08.01.05 Formulary NICE TA542 Cabozantinib for untreated advanced renal cell carcinoma
Canagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Canagliflozin 06.01.02.03 Formulary NICE TA315: Canagliflozin for type 2 diabetes
Cangrelor 02.09 Non Formulary NICE TA351: Reducing Artherothrombotic Events
Cannabidiol 10.02.02 Restricted Use TA615 Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome
Cannabidiol 10.02.02 Restricted Use TA614 Cannabidiol with clobazam for treating seizures associated with Dravet syndrome
Cannabidiol (Unlicensed formulations) 10.02.02 Restricted Use TA615 Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome
Cannabidiol (Unlicensed formulations) 10.02.02 Restricted Use TA614 Cannabidiol with clobazam for treating seizures associated with Dravet syndrome
Capecitabine 08.01.03 Formulary NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Capecitabine 08.01.03 Formulary NICE TA60: Colorectal cancer - capecitabine and tegafur uracil
Capecitabine 08.01.03 Formulary NICE TA191: Gastric cancer (advanced) - capecitabine
Carfilzomib 08.01.05 Formulary NICE TA657 Carfilzomib for previously treated multiple myeloma
Carfilzomib 08.01.05 Formulary NICE TA457 : Carfilzomib for previously treated multiple myeloma
Carmustine 08.01.01 Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Carmustine 08.01.01 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Cemiplimab 08.01.05 Formulary NICE TA592 Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma
Ceritinib 08.01.05 Formulary NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Ceritinib 08.01.05 Formulary NICE TA500 Ceritinib for untreated ALK-positive non-small-cell lung cancer
Certolizumab pegol 13.05.03.02 Formulary NICE TA574 Certolizumab pegol for treating moderate to severe plaque psoriasis
Certolizumab Pegol 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Certolizumab Pegol 10.01.03 Formulary NICE TA445 : Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARD
Certolizumab Pegol 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Certolizumab Pegol 10.01.03 Formulary NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
Cetuximab 08.01.05 Formulary NICE TA473:Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
Cetuximab 08.01.05 Formulary NICE TA439 : Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Cetuximab 08.01.05 Formulary NICE TA176: Colorectal cancer (first line) - cetuximab
Cetuximab 08.01.05 Formulary NICE TA145: Head and neck cancer - cetuximab
Ciclosporin 0.1% 11.99.99.99 Formulary NICE TA369 - Ciclosporin for treating eye disease that has not improved despite treatment with artificial tears
Cinacalcet 09.05.01.02 Formulary NICE TA117: Hyperparathyroidism - cinacalcet
Cladribine 08.01.03 Formulary TA493 Cladribine tablets for treating relapsing–remitting multiple sclerosis- This guidance has been updated and replaced by NICE technology appraisal guidance 616
Cladribine 08.01.03 Formulary TA616 Cladribine for treating relapsing–remitting multiple sclerosis
Cobimetinib 08.02.04 Non Formulary NICE TA414: Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
Colistimethate inhaler 05.01.07 Non Formulary NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
Collagenase 10.03.01 Formulary NICE TA459 : Collagenase clostridium histolyticum for treating Dupuytren’s contracture
Crizotinib 08.01.05 Formulary NICE TA529 Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
Crizotinib 08.01.05 Formulary NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Crizotinib 08.01.05 Formulary NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cance
Cytarabine liposomal 08.01.03 Formulary NICE TA552 Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia
Dabigatran 02.08.02 Formulary NICE TA249: Dabigatran for Stroke prevention in AF
Dabrafenib 08.01.05 Formulary NICE TA321:Dabrafenib for BRAF V600 +ve melanoma
Dabrafenib 08.01.05 Formulary NICE TA544 Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
Dabrafenib 08.01.05 Formulary NICE TA396:Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Daclatasvir 05.03.03.02 Formulary NICE TA364: Daclatasvir for treating chronic hepatitis C
Daclizumab 08.02.02 Non Formulary NICE TA441 : Daclizumab for treating relapsing–remitting multiple sclerosis
Dacomitinib 08.01.05 Formulary NICE TA595 Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
Dapagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA597 Dapagliflozin with insulin for treating type 1 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes
Daratumumab 08.01.05 Formulary NICE TA510 Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
Daratumumab 08.01.05 Formulary NICE TA573 Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
Darbepoetin Alfa 09.01.03 Formulary NICE CG114: Anaemia in chronic kidney disease
Darbepoetin Alfa 09.01.03 Formulary NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
Darolutamide 08.03.04.02 Formulary NICE TA660 Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer
Dasabuvir 05.03.03.02 Formulary NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Dasatinib 08.01.05 Formulary NICE TA241: CML where treatment with imatinib has failed
Dasatinib 08.01.05 Formulary NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Dasatinib 08.01.05 Formulary NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Decitabine 08.01.03 Non Formulary NICE TA548 Decitabine for untreated acute myeloid leukaemia (terminated appraisal)
Decitabine 08.01.03 Non Formulary NICE TA270: Leukaemia (acute myeloid ) - decitabine (terminated appraisal)
Degarelix 08.03.04.02 Formulary NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer
Dexamethasone 700mcg 11.99.99.99 Formulary NICE TA349: Diabetic Macular Oedema
Dexamethasone 700mcg 11.99.99.99 Formulary NICE TA229: Treatment of macular oedema secondary to retinal vein occlusion
Dimethyl fumarate 08.02.04 Formulary NICE TA320: Dimethyl fumarate for multiple sclerosis
Dimethyl fumarate 13.05.03 Formulary NICE TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis
Docetaxel 08.01.05 Formulary NICE TA109: Breast cancer (early) - docetaxel
Docetaxel 08.01.05 Formulary NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
Donepezil 04.11 Formulary NICE TA217 Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Doxorubicin 08.01.02 Formulary NICE TA440 : Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine
Doxorubicin 08.01.02 Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Dronedarone 02.03.02 Formulary NICE TA197: Atrial fibrillation - dronedarone
Durvalumab 08.01.05 Formulary NICE TA662 Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal)
Durvalumab 08.01.05 Formulary NICE TA578 Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation
Edoxaban 02.08.02 Formulary NICE TA355:Edoxaban for preventing stroke/systemic embolism in non‑valvular atrial fibrillation
Elbasvir/Grazoprevir 05.03.03.02 Formulary NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C
Eltrombopag 09.01.04 Formulary NICE TA293: Eltrombopag for treating chronic ITP
Eluxadoline 01.04.02 Formulary NICE TA471: Eluxadoline for treating irritable bowel syndrome with diarrhoea
Empagliflozin 06.01.02.03 Formulary NICE TA336: Empagliflozin for type 2 diabetes
Empagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Entecavir 05.03.03.01 Formulary NICE CG165: Hepatitis B (incorporates TA153)
Entecavir 05.03.03.01 Formulary NICE TA153: Hepatitis B (chronic) - etecavir
Entrectinib 08.01.05 Formulary TA644 Enrectinib for treating NTRK fusion-positive solid tumours
Entrectinib 08.01.05 Formulary TA643: Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer
Enzalutamide 08.03.04.02 Formulary NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Enzalutamide 08.03.04.02 Formulary NICE TA316: Enzalutamide for prostate cancer
Enzalutamide 08.03.04.02 Formulary NICE TA580 Enzalutamide for hormone-relapsed non-metastatic prostate cancer
Eplerenone 02.02.03 Formulary NICE CG108: Chronic heart failure
Epoetin alfa 09.01.03 Formulary NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
Epoetin alfa 09.01.03 Formulary NICE CG114: Anaemia in chronic kidney disease
Epoetin beta 09.01.03 Formulary NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
Epoetin beta 09.01.03 Formulary NICE CG114: Anaemia in chronic kidney disease
Eribulin 08.01.05 Formulary NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
Eribulin 08.01.05 Formulary NICE TA515 Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen
Ertugliflozin 06.01.02.03 Restricted Use NICE TA583 Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes
Ertugliflozin 06.01.02.03 Restricted Use NICE TA572 Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes
Etanercept 13.05.03.02 Formulary NICE TA103: Psoriasis - efalizumab and etanercept
Etanercept 10.01.03 Formulary NICE TA455 : Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Etanercept 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for JIA
Etanercept 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Etanercept 10.01.03 Formulary NICE TA199: Psoriatic arthritis
Etanercept 10.01.03 Formulary NICE TA195: Rheumatoid arthritis after the failure of a TNF inhibitor
Etanercept 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Etanercept 10.01.03 Formulary NICE TA35: Adult psoriasis
Etelcalcetide 09.05.01.02 Formulary NICE TA448 : Etelcalcetide for treating secondary hyperparathyroidism
Everolimus 08.01.05 Formulary NICE TA348: Preventing Rejection in Liver Transplant
Everolimus 08.01.05 Formulary NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Everolimus 08.01.05 Formulary NICE TA449 : Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Everolimus 08.01.05 Non Formulary NICE TA449 : Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Evolocumab 02.12 Formulary NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Exenatide prolonged release 06.01.02.03 Formulary NICE TA248: MR exenatide
Ezetimibe 02.12 Formulary NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
Febuxostat 10.01.04 Formulary NICE TA164: Hyperuricaemia - febuxostat
Finasteride 06.04.02 Formulary NICE CG97 Lower urinary tract symptoms: quick reference guide
Fingolimod 08.02.04 Formulary NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis
Fludarabine Phosphate 08.01.03 Formulary NICE TA119: Leukaemia (lymphocytic) - fludarabine
Fludarabine Phosphate 08.01.03 Formulary NICE TA29: Leukaemia (lymphocytic) - fludarabine
Fludarabine Phosphate 08.01.03 Formulary TA640: Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant
Fluocinolone 190mcg/ml 11.99.99.99 Formulary NICE TA301: Treating chronic diabetic macular oedema after an inadequate response to prior therapy
Fluocinolone 190mcg/ml 11.99.99.99 Formulary NICE TA590 Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis
Fremanezumab 04.07.04.02 Formulary TA631 Fremanezumab for preventing migraine
Fulvestrant 08.03.04.01 Formulary NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer
Fulvestrant 08.03.04.01 Formulary NICE TA503 Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer
Fulvestrant 08.03.04.01 Formulary NICE TA593 Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
Fulvestrant 08.03.04.01 Formulary NICE TA579 Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
Galantamine XL 04.11 Formulary NICE TA217 Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Galcanezumab 04.07.04.02 Formulary NICE TA659 Galcanezumab for preventing migraine
Gemcitabine 08.01.03 Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Gemcitabine 08.01.03 Formulary NICE TA25: Pancreatic cancer - gemcitabine
Gemcitabine 08.01.03 Formulary NICE TA116: Breast cancer - gemcitabine
GEMTUZUMAB - OZOGAMICIN Injection 5 mg 20 Formulary NICE TA545 Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
Gilteritinib 08.01.05 Formulary TA642 Gilteritinib for treating relapsed or refractory acute myeloid leukaemia
Glatiramer Acetate 08.02.04 Formulary NICE CG32: Glatiramer for the treatment of MS
GLIADEL wafer Carmustine 7.6mg 20 Non Formulary NICE TA121: Glioma - carmustine implants and temozolomide
Golimumab 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Golimumab 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Golimumab 10.01.03 Formulary NICE TA220: psoriatic arthritis
Golimumab 10.01.03 Formulary TA497 Golimumab for treating non-radiographic axial spondyloarthritis
Golimumab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Guselkumab 13.05.03.02 Formulary NICE TA521 Guselkumab for treating moderate to severe plaque psoriasis
Ibrutinib 08.01.05 Formulary NICE TA429 : Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Ibrutinib 08.01.05 Formulary NICE TA608 Ibrutinib with rituximab for treating Waldenstrom’s macroglobulinaemia (terminated appraisal)
Ibrutinib 08.01.05 Formulary NICE TA502 Ibrutinib for treating relapsed or refractory mantle cell lymphoma
Idelalisib 08.01.05 Formulary NICE TA359: Chronic lymphocytic leukaemia - Idelalisib
Infliximab 01.05.03 Non Formulary NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
Infliximab 01.05.03 Non Formulary NICE TA187: Crohns disease - infliximab & adalimumab
Infliximab 01.05.03 Non Formulary NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Infliximab 13.05.03.02 Formulary NICE TA134: Infliximab for psoriasis
Infliximab 10.01.03 Formulary NICE TA195: Rheumatoid arthritis (after failure of a TNF inhibitor)
Infliximab 10.01.03 Formulary NICE TA199: Psoriatic arthritis
Infliximab 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Infliximab 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Infliximab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Infliximab 01.05.03 Formulary NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
Infliximab 01.05.03 Formulary NICE TA187: Crohns disease - infliximab & adalimumab
Inotuzumab ozogamicin 08.01.05 Formulary TA 541 Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
Interferon Alfa 08.02.04 Formulary NICE TA75: Interferon Alfa - Chronic Hepatitis C
Interferon Beta 08.02.04 Formulary NICE TA527 Beta interferons and glatiramer acetate for treating multiple sclerosis
Interferon Beta 08.02.04 Formulary NICE TA32: Interferon Beta for MS
Interferon Beta 08.02.04 Formulary NICE TA527 Beta interferons and glatiramer acetate for treating multiple sclerosis
Ipilimumab 08.01.05 Formulary NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Ipilimumab 08.01.05 Formulary NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
Ipilimumab 08.01.05 Formulary NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Isatuximab 08.02.03 Formulary NICE TA658 Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma
Ivabradine 02.06.03 Formulary NICE TA267- Heart Failure
Ivabradine 02.06.03 Non Formulary NICE CG126: Guidance on Stable Angina (2011)
Ivermectin 13.10.04 Formulary Ivermectin-Prescribing advice
Ixazomib 08.01.05 Formulary NICE TA505 Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
Ixekizumab 13.05.03.02 Formulary NICE TA442 : Ixekizumab for treating moderate to severe plaque psoriasis
Lamivudine 05.03.03.01 Formulary NICE TA165 Hepatitis B (chronic): diagnosis and management
Lamivudine 05.03.03.01 Formulary NICE CG165: Chronic Hepatitis B
Lanadelumab 03.04.03 Formulary NICE TA606 Lanadelumab for preventing recurrent attacks of hereditary angioedema
Lapatinib 08.01.05 Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Larotrectinib 08.01 Formulary TA630 Larotrectinib for treating NTRK fusion-positive solid tumours
Ledipasvir and Sofosbuvir 05.03.03.02 Formulary NICE TAG63: Ledipasvir–sofosbuvir for treating chronic hepatitis C
Ledipasvir and Sofosbuvir 05.03.03.02 Formulary NICE TA430 : Sofosbuvir–velpatasvir for treating chronic hepatitis C
Lenalidomide 08.02.04 Formulary NICE TA586 Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib
Lenalidomide 08.02.04 Formulary NICE TA322 Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
Lenalidomide 08.02.04 Formulary NICE TA171 Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies
Lenalidomide 08.02.04 Formulary NICE TA603 Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal)
Lenalidomide 08.02.04 Formulary NICE TA587 Lenalidomide plus dexamethasone for previously untreated multiple myeloma
Lenalidomide 08.02.04 Formulary NICE TA627 Lenalidomide with rituximab for previously treated follicular lymphoma
Lenvatinib 08.01.05 Formulary NICE TA551 Lenvatinib for untreated advanced hepatocellular carcinoma
Lenvatinib 08.01.05 Formulary NICE TA498 Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
Lesinurad 10.01.04 Non Formulary NICE TA506 Lesinurad for treating chronic hyperuricaemia in people with gout
Lorlatinib 08.01 Formulary TA628 Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer
Lubiprostone 01.06.07 Non Formulary NICE TA318: Lubiprostone for treating chronic idiopathic constipation
Lumacaftor + Ivacaftor 03.07 Non Formulary NICE TA398: Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation
Lusutrombopag tablets 09.01.04 Formulary TA617 Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure
Mannitol inhalation 03.07 Restricted Use NICE TA266: Cystic fibrosis - mannitol dry powder for inhalation
Memantine 04.11 Formulary NICE TA217 Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Mepolizumab 03.04.02 Non Formulary NICE TA431 : Mepolizumab for treating severe refractory eosinophilic asthma
Methylprednisolone 06.03.02 Formulary NICE CG186: Multiple Sclerosis; management in primary and secondary care.
Midostaurin 08.01.05 Formulary NICE TA523 Midostaurin for untreated acute myeloid leukaemia
Mifamurtide 08.02.04 Non Formulary NICE TA235: Osteosarcoma - mifamurtide: guidance
Milrinone 02.01.02 Non Formulary NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Mirabegron 07.04.02 Formulary NICE TA290: Mirabegron for overactive bladder
Naftidrofuryl 02.06.04 Formulary NICE CG147: Lower limb peripheral arterial disease management
Naftidrofuryl 02.06.04 Formulary NICE TA223: Intermittent claudication drugs
Nalmefene 04.10.01 Formulary NICE TA325 Nalmefene for reducing alcohol consumption in people with alcohol dependence
Naloxegol 01.06.06 Formulary NICE TA345-Naloxegol for treating opioid‑induced constipation
Naltrexone 04.10.03 Formulary NICE TA115: Drug misuse - naltrexone
Naltrexone/ bupropion 04.05.01 Non Formulary NICE TA494: Naltrexone–bupropion for managing overweight and obesity
Natalizumab 08.02.04 Non Formulary NICE TA127: Multiple sclerosis - natalizumab
Necitumumab 08.01.05 Non Formulary NICE TA411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer
Nilotinib 08.01.05 Formulary NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Nilotinib 08.01.05 Formulary NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Nilotinib 08.01.05 Formulary NICE TA251: Dasatinib, nilotinib and imatinib for first line treatment of CML
Nilotinib 08.01.05 Formulary NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML
Nintedanib 03.11 Non Formulary NICE TA379:Nintedanib for treating idiopathic pulmonary fibrosis
Nintedanib 03.11 Non Formulary NICE TA347: Recurrent non-small-cell lung cancer
Niraparib 08.01.05 Formulary NICE TA528 Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
Nivolumab 08.02.04 Formulary NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma
Nivolumab 08.02.04 Formulary NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
Nivolumab 08.02.04 Formulary NICE TA462 : Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
Nivolumab 08.02.04 Formulary NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Nivolumab 08.02.04 Formulary NICE TA490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy
Nivolumab 08.02.04 Formulary NICE TA530 Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy
Nivolumab 08.02.04 Formulary NICE TA558 Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
Nivolumab 08.02.04 Formulary NICE TA581 Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
Nusinersen 10.02.01 Non Formulary NICE TA588 Nusinersen for treating spinal muscular atrophy
Obeticholic acid 01.09.01 Non Formulary NICE TA443 : Obeticholic acid for treating primary biliary cholangitis
Obinutuzumab 08.02.03 Formulary NICE TA 513 Obinutuzumab for untreated advanced follicular lymphoma
Obinutuzumab 08.02.03 Formulary NICE TA629 Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab
Obinutuzumab 08.02.03 Formulary NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab
Obinutuzumab 08.02.03 Formulary NICE TA343: Obinutuzumab with chlorambucil for CLL
Ocrelizumab 08.02.04 Formulary NICE TA585 Ocrelizumab for treating primary progressive multiple sclerosis
Ocrelizumab 08.02.04 Formulary NICE TA533 Ocrelizumab for treating relapsing–remitting multiple sclerosis
Ocriplasmin 0.5mg/0.2ml 11.99.99.99 Formulary NICE TA297: Ocriplasmin for treating vitreomacular traction
Ofatumumab 08.02.03 Formulary NICE TA344: Ofatumumab with chlorambucil or bendamustine for CLL
Olaparib 08.02.04 Formulary NICE TA620 Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
Olaparib 08.02.04 Formulary NICE TA598 Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
Olaparib 08.02.04 Formulary NICE TA381: Olaparib guidance
Olaratumab 08.01.05 Non Formulary NOCE TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma
Omalizumab 13.05.03 Formulary Omalizumab for previously treated chronic spontaneous urticaria
Omalizumab 03.04.02 Formulary NICE TA278: Omalizumab for treating allergic asthma
Omalizumab 03.04.02 Formulary NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria
Ombitasvir/ paritaprevir/ ritonavir 05.03.03.02 Formulary NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Orlistat 04.05.01 Formulary NICE CG189-Obesity: identification, assessment and management
Osimertinib 08.02.04 Formulary NICE TA621 Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer
Osimertinib 08.02.04 Formulary NICE TA654 Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer
Osimertinib 08.02.04 Formulary NICE TA653 Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer
Osimertinib 08.02.04 Formulary NICE TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer
Oxaliplatin 08.01.05 Formulary NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Pabrinex® 09.06.02 Formulary NICE CG115: Alcohol dependence - diagnosis, assessment and management
Pabrinex® 09.06.02 Formulary NICE CG100: Management of alcohol-related physical complications
Paclitaxel 08.01.05 Formulary NICE TA108: Breast cancer (early) - paclitaxel
Paclitaxel 08.01.05 Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Paclitaxel - Albumin Bound Formulation 08.01.05 Formulary NICE TA360: Pancreatic cancer - paclitaxel with gemcitabine
Palbociclib 08.03.04.01 Formulary NICE TA619 Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
Palbociclib 08.03.04.01 Formulary TA495 Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Panitumumab 08.01.05 Formulary NICE TA439 : Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Panobinostat 08.01.05 Formulary NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
Pazopanib 08.01.05 Formulary NICE TA215: Pazopanib in renal cell cancer
Peginterferon Alfa 08.02.04 Formulary NICE TA106: Hepatitis C - peginterferon alfa & ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon
Peginterferon Alfa 08.02.04 Formulary NICE TA200: Hepatitis C - peginterferon alfa & ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE TA96: Hepatitis B - peginterferon alfa
Peginterferon Alfa 08.02.04 Formulary NICE TA300: Hepatitis C - peginterferon alfa
Pegloticase 20 Non Formulary NICE TA291: Pegloticase not recommended for severe chronic gout
Pembrolizumab 08.01.05 Formulary NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
Pembrolizumab 08.01.05 Formulary NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Pembrolizumab 08.01.05 Formulary NICE TA447 : Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Pembrolizumab 08.01.05 Formulary NICE TA357: Pembrolizumab for melanoma after ipilimumab
Pembrolizumab 08.01.05 Formulary NICE TA540 Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
Pembrolizumab 08.01.05 Formulary NICE TA519 Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Pembrolizumab 08.01.05 Formulary NICE TA661 Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma
Pembrolizumab 08.01.05 Formulary NICE TA531 Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Pembrolizumab 08.01.05 Formulary NICE TA553 Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
Pembrolizumab 08.01.05 Formulary NICE TA522 Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Pembrolizumab 08.01.05 Formulary NICE TA557 Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
Pembrolizumab 08.01.05 Formulary NICE TA600 Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
Pembrolizumab 08.01.05 Formulary NICE TA570 Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal)
Pemetrexed 08.01.03 Formulary NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance)
Pemetrexed 08.01.03 Formulary NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed
Pemetrexed 08.01.03 Formulary NICE TA135: Mesothelioma - pemetrexed disodium
Pemetrexed 08.01.03 Formulary NICE TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin
Perampanel 04.08.01 Restricted Use NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
Pertuzumab 08.01.05 Formulary NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
Pertuzumab 08.01.05 Formulary TA509 Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Pimecrolimus 13.05.03 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Pirfenidone 03.11 Formulary NICE TA504 Pirfenidone for treating idiopathic pulmonary fibrosis
Pirfenidone 03.11 Formulary NICE TA282: Idiopathic pulmonary fibrosis - pirfenidone
Pixantrone 08.01.02 Non Formulary NICE TA306: Pixantrone monotherapy
Pomalidomide 08.02.04 Formulary NICE TA658 Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma
Pomalidomide 08.02.04 Formulary NICE TA602 Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)
Pomalidomide 08.02.04 Formulary NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
Pomalidomide 08.02.04 Formulary NICE TA388: Pomalidomide for myeloma
Ponatinib 08.01.05 Non Formulary NICE TA451 : Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
Prasugrel 02.09 Formulary NICE TA317 (replaces TA182): Acute coronary syndrome - prasugrel
Prolia® 06.06.02 Restricted Use NICE TA204: Osteoporotic fractures - denosumab
Prucalopride 01.06.07 Formulary NICE TA211: Constipation (women) - prucalopride
Radium-223 dichloride 08.03.04.02 Non Formulary NICE TA376: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
Radium-223 dichloride 08.03.04.02 Non Formulary NICE TA412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
Raloxifene Hydrochloride 06.04.01.01 Formulary NICE TA160 Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women
Raloxifene Hydrochloride 06.04.01.01 Formulary NICE TA161-Secondary prevention of osteoporotic fragility fractures in postmenopausal women
Ramucirumab 08.01.05 Non Formulary NICE TA403: Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
Ramucirumab 08.01.05 Non Formulary NICE TA609 Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal)
Ranibizumab 10mg/ml 11.99.99.99 Formulary NICE TA298:Ranibizumab for treating choroidal neovascularisation associated with pathological myopia
Ranibizumab 10mg/ml 11.99.99.99 Formulary NICE TA155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration
Ranibizumab 10mg/ml 11.99.99.99 Formulary NICE TA274:Ranibizumab for treating diabetic macular oedema
Ranibizumab 10mg/ml 11.99.99.99 Formulary NICE TA283: Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion
Ranolazine 02.06.03 Formulary NICE CG126: Guidance on Stable Angina (2011)
Regorafenib 08.01.05 Formulary NICE TA514 Regorafenib for previously treated advanced hepatocellular carcinoma
Regorafenib 08.01.05 Formulary NICE TA555 Regorafenib for previously treated advanced hepatocellular carcinoma
Retigabine 04.08.01 Formulary NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation
Ribavirin 05.03.05 Non Formulary NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 05.03.05 Non Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Ribavirin 05.03.05 Non Formulary NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Ribociclib 08.03.04.01 Formulary TA496 Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Ribociclib 08.03.04.01 Formulary NICE TA593 Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
Riluzole 04.09.03 Formulary NICE TA20: Motor neurone disease - riluzole
Risankizumab 13.05.03.02 Formulary NICE TA596 Risankizumab for treating moderate to severe plaque psoriasis
Rituximab 08.02.03 Formulary NICE TA609 Ibrutinib with rituximab for treating Waldenstrom’s macroglobulinaemia (terminated appraisal)
Rituximab 08.02.03 Formulary NICE TA561 Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
Rituximab (rheumatology) 10.01.03 Formulary NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor
Rivaroxaban 02.08.02 Formulary NICE TA607 Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease
Roflumilast 03.03.03 Formulary NICE TA244: Chronic obstructive pulmonary disease - roflumilast (only as part of a trial)
Roflumilast 03.03.03 Formulary NICE TA461 : Roflumilast for treating chronic obstructive pulmonary disease
Romiplostim 09.01.04 Formulary NICE TA221: Thrombocytopenic purpura - romiplostim
Ruxolitinib 08.01.05 Formulary NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
Sacubitril valsartan 02.05.05.02 Formulary NICE TA388: Sacubitril valsartan for heart failure (updated 16/7/16 to include adoption resources)
Sarilumab 10.01.03 Formulary NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis
Secukinumab 10.01.03 Formulary NICE TA407 Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
Secukinumab 10.01.03 Formulary NICE TA455:Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Secukinumab 13.05.03.02 Formulary NICE TA350: Plaque Psoriasis
Secukinumab 13.05.03.02 Formulary NICE TA445: Secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Simeprevir 05.03.03.02 Formulary NICE TA331: Simeprevir with peginterferon alfa & ribavirin for hepatitis C
Siponimod 08.02.04 Formulary NICE TA656 Siponimod for treating secondary progressive multiple sclerosis
Sipuleucel- T 20 Non Formulary NICE TA322: Sipuleucel-T for prostate cancer
Sodium zirconium cyclosilicate 09.02.01.01 Formulary Sodium zirconium cyclosilicate for treating hyperkalaemia Technology appraisal guidance [TA599]
Sofosbuvir 05.03.03.02 Formulary NICE TA330: Sofosbuvir for treating chronic hepatitis C
Sofosbuvir/velpatasvir/voxilaprevir 05.03.03.02 Formulary Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C
Somatropin 06.05.01 Formulary NICE TA188: Somatropin for growth failure in children
Somatropin 06.05.01 Formulary NICE TA64: Growth hormone deficiency (adults)
Sunitinib 08.01.05 Formulary NICE TA169: Renal cell carcinoma - sunitinib
Sunitinib 08.01.05 Formulary NICE TA449 : Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Sunitinib 08.01.05 Formulary NICE TA179: Gastrointestinal stromal tumours - sunitinib
Tacrolimus 13.05.03 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Tadalafil 07.04.05 Non Formulary NICE TA273: Hyperplasia (benign prostatic) - tadalafil (terminated appraisal)
Talimogene laherparepvec 08.01.05 Non Formulary NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma
Tegafur with Uracil 08.01.03 Formulary NICE TA61: Capcitabine and tegafur - Colorectal cancer
Telaprevir 05.03.03.02 Formulary NICE TA252: Telaprevir in hepatitis C
Temozolomide 08.01.05 Formulary NICE TA121: Glioma (newly diagnosed and high grade)
Temozolomide 08.01.05 Formulary NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
Tenofovir disoproxil 05.03.03.01 Formulary NICE TA173 Tenofovir disoproxil for the treatment of chronic hepatitis B
Tenofovir Disproxil 05.03.03.01 Formulary NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil
Teriflunomide 08.02.04 Formulary NICE TA405:Trifluridine–tipiracil for previously treated metastatic colorectal cancer
Teriflunomide 08.02.04 Formulary NICE TA303: Teriflunomide for relapsing remitting MS
Teriparatide 06.06.01 Restricted Use NICE TA161-Secondary prevention of osteoporotic fragility fractures in postmenopausal women
Thiamine 09.06.02 Formulary NICE CG100: Management of alcohol-related physical complications
Thiamine 09.06.02 Formulary NICE CG115: Alcohol dependence - diagnosis, assessment and management
Ticagrelor 02.09 Formulary NICE TA236: Ticagrelor for the treatment of acute coronary syndromes
Ticagrelor 02.09 Formulary NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction
Tildrakizumab 13.05.03.02 Formulary NICE TA575 Tildrakizumab for treating moderate to severe plaque psoriasis
Tivozanib 08.01.05 Formulary NICE TA 512 Tivozanib for treating advanced renal cell carcinoma
Tobramycin inhaler 05.01.04 Non Formulary NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
Tocilizumab 10.01.03 Formulary NICE TA247:Tocilizumab in RA
Tocilizumab 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Tocilizumab 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Tocilizumab 10.01.03 Formulary NICE TA518 Tocilizumab for treating giant cell arteritis
Tofacitinib 01.05.03 Formulary NICE TA547 Tofacitinib for moderately to severely active ulcerative colitis
Tofacitinib 10.01.03 Formulary NICE TA480:Tofacitinib for moderate to severe rheumatoid arthritis
Tofacitinib 10.01.03 Formulary NICE TA543 Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
Tolvaptan 06.05.02 Formulary NICE TA358: Autosomal dominant polycystic kidney disease - tolvaptan
Tolvaptan 06.05.02 Non Formulary NICE TA358: Autosomal dominant polycystic kidney disease - tolvaptan
Topotecan 08.01.05 Formulary NICE TA183: Cervical cancer (recurrent) - topotecan
Topotecan 08.01.05 Formulary NICE TA184: Lung cancer (small-cell) - topotecan
Topotecan 08.01.05 Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Trabectedin 08.01.05 Formulary NICE TA185: Soft tissue sarcoma - trabectedin
Trabectedin 08.01.05 Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Trametinib 08.01.05 Formulary NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Trametinib 08.01.05 Formulary NICE TA544 Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
Trastuzumab 08.01.05 Formulary NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Trastuzumab 08.01.05 Formulary TA509 Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Trastuzumab 08.01.05 Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Trastuzumab 08.01.05 Formulary NICE TA34: Breast cancer - trastuzumab
Trastuzumab emtansine 08.01.05 Formulary NICE TA458 : Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxan
Trastuzumab emtansine 08.01.05 Formulary TA632 Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer
Treosulfan 08.01.01 Formulary TA640: Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant
Ustekinumab 13.05.03.02 Formulary NICE TA180: Psoriasis - ustekinumab
Ustekinumab 13.05.03.02 Formulary NICE TA340: Ustekinumab for treating active psoriatic arthritis
Ustekinumab 13.05.03.02 Formulary NICE TA455 : Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young peopl
Ustekinumab 13.05.03.02 Formulary NICE TA456 : Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
Ustekinumab 01.05.03 Formulary TA633: Ustekinumab for treating moderately to severely active ulcerative colitis
Ustekinumab 10.01.03 Formulary NICE TA340:Ustekinumab for treating active psoriatic arthritis
Ustekinumab 10.01.03 Formulary NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Vandetanib 08.01.05 Formulary NICE TA550 Vandetanib for treating medullary thyroid cancer
Varenicline 04.10.02 Formulary NICE TA123: Varenicline
Vedolizumab 01.05.03 Formulary NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
Vedolizumab 01.05.03 Formulary NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis
Vemurafenib 08.01.05 Formulary NICE TA269: Vemurafenib for treating malignant melanoma
Verteporfin 11.08.02 Non Formulary NICE TA68: Photodynamic therapy for age related macular degeneration
Victoza® 06.01.02.03 Formulary NG28: Type 2 diabetes in adults: management
Vinflunine 08.01.04 Formulary NICE TA272: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine
Vortioxetine 04.03.03 Formulary NICE TA367 - Vortioxetine for treating major depressive episodes
XGEVA® 06.06.02 Formulary NICE TA265: Bone metastases from solid tumours - denosumab: guidance
XGEVA® 06.06.02 Formulary NICE TA549 Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal)
Zolpidem 04.01.01 Formulary NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia
Zopiclone 04.01.01 Formulary NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia